Bellicum Pharmaceuticals (BLCM)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final voting results with respect to each matter:

Proposal 1. Election of Directors

The Company’s stockholders elected the person listed below as a Class II Director, to serve until the Company’s 2025 annual meeting of stockholders and until their successor is duly elected and qualified. The final voting results are as follows:
Name of Director NomineeVotes ForVotes WithheldBroker Non-Votes
Judith Klimovsky, M.D.1,723,047152,8132,985,038

Proposal 2. Approval of the Plan Amendment

The Company’s stockholders approved the Amended 2019 Plan. The final voting results were as follows:
Votes ForVotes AgainstAbstentionsBroker Non-Votes

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:
Votes ForVotes AgainstAbstentions

Proposal 4. Advisory Vote on Executive Compensation

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits
Exhibit NumberDescription
10.1Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)